Clinical Trials
1
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1961
Unknown
1
100.0%
No approval data available
- Teva Pharmaceuticals has asked a Philadelphia federal court to prevent Humana from identifying it as an Israeli company during an upcoming price-fixing trial, arguing the Gaza war has created widespread anti-Israel sentiment that could prejudice jurors. - The trial, scheduled to begin September 15, involves allegations that Teva and other drug makers conspired to inflate prices of generic drugs including baclofen and propranolol. - Teva cited polling showing 60% of Americans hold a negative view of Israel and pointed to campus protests and acts of violence against Israel-affiliated entities as evidence of potential juror bias. - Humana separately requested the court bar defendants from introducing inflammatory evidence about health insurers, referencing the 2024 killing of UnitedHealthcare's CEO.
- Thyme Care raised $125 million in a Series E round led by Morgan Health, roughly doubling its valuation to more than $2 billion less than a year after its Series D. - The cancer care navigation startup now serves more than 10.5 million people across all 50 U.S. states and manages over $7 billion in oncology spend, with revenue surpassing $125 million last year. - Founder Robin Shah will lead a new parent company, Thyme Companies, focused on cancer drug affordability through biosimilars and improving clinical trial access and navigation. - The company reports profitability and positive free cash flow, and its care management reduced emergency room admissions by 28% for the patients it serves.
- Costco and not-for-profit insurer SCAN Group announced a partnership to launch a Costco-branded Medicare Advantage plan, initially in two states. - SCAN Group CEO Dr. Sachin Jain said the companies are also developing a Medigap supplemental plan for a third state, pending regulatory approval. - The collaboration builds on Costco's existing role as a preferred pharmacy for SCAN's nearly 460,000 Medicare Advantage members across five states. - The move deepens Costco's push into healthcare as some insurers scale back Medicare Advantage ambitions amid rising medical costs and tighter reimbursement.
- Alignment Healthcare's second quarter net income more than doubled to $36.6 million, or 17 cents per share, compared to $15.65 million, or 7 cents per share, a year earlier. - The company's medical benefit ratio dropped to 86.3%, an improvement of roughly 40 basis points year-over-year, marking the second consecutive quarter of decline. - Total revenue rose more than 31% to $1.3 billion, driven by 31% growth in Medicare Advantage membership to 294,100 members. - Founder and CEO John Kao attributed the results to investments in the company's clinical model, AI-enabled capabilities, and operational infrastructure.
- Mark Cuban's Cost Plus Drug Company has formed a strategic partnership with Humana's CenterWell Pharmacy to develop new end-to-end employer prescription solutions aimed at reducing drug costs for corporate health plans. - The collaboration combines Cost Plus Drugs' transparent pricing model and SwiftyRx technology platform with CenterWell's distribution infrastructure, targeting employers seeking alternatives to traditional pharmacy benefit managers. - CenterWell Pharmacy will use Cost Plus Drugs' SwiftyRx software-as-a-service solution for medication order intake operations, with the goal of simplifying medication access and lowering patient costs through streamlined processes. - The partnership comes as U.S. employer healthcare costs are projected to rise more than 9% this year, exceeding $17,000 per employee, driven partly by rising prescription drug costs.
- CenterWell Pharmacy, Humana's specialty pharmacy division, announced a strategic partnership with Eli Lilly to dispense FDA-approved obesity management medications through employer-sponsored carve-out programs. - The initiative addresses rising prescription drug costs for employers, with 79% reporting increased GLP-1 usage, while providing more affordable access to weight-loss medications for employees. - The program operates through approved third-party entities where employees receive prescriptions, which are then fulfilled by CenterWell with comprehensive pharmacy services including clinical support and care navigation.
- TempraMed Technologies has launched VIVI Cap Smart, the world's first platform that combines temperature protection with digital tracking for insulin and GLP-1 pens. - The device integrates proprietary space-grade thermal insulation technology with digital health functionality, enabling automatic injection timing tracking and medication logging through a connected mobile application. - This launch represents TempraMed's strategic transition toward a comprehensive patient platform that combines physical device innovation with digital tools for chronic disease management. - The company has already achieved significant commercial traction with over 120,000 devices sold globally and distribution through major retailers and healthcare organizations including Maccabi Healthcare Services.
• Glenmark Pharmaceuticals has agreed to pay $7 million to settle antitrust lawsuits with three major healthcare entities - Humana, Centene, and Kaiser - over generic cholesterol medications Zetia and Vytorin. • The lawsuits alleged that Glenmark entered an anticompetitive agreement in 2010 with Schering Corporation and MSP Singapore Company LLC regarding patent infringement litigation for ezetimibe. • While reaching the settlement agreement, Glenmark explicitly denies all allegations and maintains the settlement does not indicate any admission of liability or illegal conduct.
• A comprehensive analysis of Medicare Part D claims reveals that CVS, Humana, Cigna, and UnitedHealth Group control 34.1% of all pharmacy spending, with even higher shares in specialty pharmacy segments. • Research demonstrates significant patient steering practices, with specialty drug claims being 19.8 percentage points more likely to be filled at insurer-PBM owned pharmacies than expected without steering. • The study highlights potential market competition concerns, particularly in specialty drug categories where insurer-PBM pharmacy control reaches up to 89.7% for certain therapeutic classes.
• The end of the Oncology Care Model has led to significant reductions in value-based care volumes, prompting concerns about sustaining extended patient services and equitable care delivery in oncology practices. • The Inflation Reduction Act's drug price negotiations could result in up to 49% reimbursement cuts for oncology providers, raising alarms about the financial sustainability of community practices. • Industry experts emphasize urgent need for pharmacy benefit manager (PBM) reform, calling for increased transparency and policy changes to address spread pricing and rebate schemes affecting biosimilar adoption.
